US 7,482,149 B2
	Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
Emily Li Chuan Tan, Singapore (Singapore); and Lawrence W. Stanton, Singapore (Singapore)
Assigned to Genome Institute of Singapore, Singapore (Singapore)
Appl. No. 10/560,198 PCT Filed Jun. 09, 2004, PCT No. PCT/SG2004/000173 § 371(c)(1), (2), (4) Date Dec. 08, 2005, PCT Pub. No. WO2004/108151, PCT Pub. Date Dec. 16, 2004.
Claims priority of provisional application 60/476611, filed on Jun. 09, 2003.
Prior Publication US 2006/0153803 A1, Jul. 13, 2006
Int. Cl. C12N 7/00 (2006.01); C12N 7/06 (2006.01); A61K 38/21 (2006.01)

U.S. Cl. 435—235.1  [435/238; 424/85.6; 424/85.7]

8 Claims

1. A method of inhibiting SARS-coronavirus infection, comprising administering an interferon to an in vitro cell capable of being infected with SARS-CoV, wherein the interferon is IFN α-n1, IFN α-n3, human leukocyte IFN α or IFN β-1b.